BioVie - Class A opened lower at $1.24, compared with its previous close of $1.26. In the last trading session, the stock traded between $1.16 and $1.24. It showed a downward intraday trend.
An investment of $100 made 5 years ago in BioVie - Class A is now worth
$ 0.19
Resulting in a loss of
$ 99.81 (99.81%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
$-0.07 (-5.48%)
Day High
$1.24
Day Low
$1.16
Day Open
$1.24
Prev Close
$1.26
Volume
1,60,348
1W Return
-9.08%
1M Return
-10.11%
3M Return
-5.85%
6M Return
-11.78%
1Y Return
-21.13%
Market Cap ($ Mn)
13
PE Ratio
-
PB Ratio
1.60
PEG Ratio
-
ROE
-92.99%
ROCE
-94.18%
EPS (TTM)
$-0.65
1 Week
-9.08%
1 Month
-10.11%
3 Months
-5.85%
6 Months
-11.78%
9 Months
3.57%
BioVie reveals distinct Long COVID endotypes in ADDRESS-LC trial
BioVie Inc. presented new biomarker data from the Phase 2 ADDRESS-LC trial. High-inflammatory endotype patients showed improved objective cognitive impairment. Low-myeloid endotype patients experienced reduced fatigue and post-exertional malaise. Data suggests single efficacy endpoints may miss clinically meaningful responses.
3 days agoBioVie secures $4.74M in registered direct offering and private placement
BioVie Inc. announced a $4.74 million registered direct offering and concurrent private placement. The company sold 2,962,500 shares at $1.60 per share to a single healthcare-focused institutional investor. Concurrent private placement includes unregistered common warrants exercisable at $1.70 per share. Net proceeds will be used for working capital and general corporate purposes.
8 days agoBioVie reports Phase 2 data on Long COVID treatment at ANA meeting
BioVie Inc. presented Phase 2 ADDRESS-LC trial results for bezisterim at the ANA annual meeting. The study evaluated bezisterim (NE3107) in patients suffering from Long COVID. Abstracts were published in Annals of Neurology alongside the October 2026 conference.
24 days agoBioVie signs $6.46m stock sales agreement with Alliance Global
BioVie Inc. signed a sales agreement with Alliance Global Partners on September 11, 2026. The deal permits the issuance of Class A common stock worth up to $6,464,341. Shares will be sold via at-the-market offerings under Rule 415 of the Securities Act. Alliance Global Partners will receive a 3.0% commission on gross proceeds. Proceeds are designated for general corporate purposes.
1mo agoBioVie Q4 Results: EPS loss narrows 51% YoY to $(0.70)
BioVie Inc. posted a Q4 EPS loss of $(0.70), down from $(1.42) in the prior year. The 50.7% YoY improvement in per-share losses signals narrowing deficits, though the company continues to report a net loss for the quarter.
3mo agoBioVie reports positive Phase 2 results for bezisterim in early Parkinson’s disease
BioVie Inc. reported positive Phase 2 results for bezisterim in early Parkinson’s disease, with significant improvements in motor/non-motor symptoms and inflammatory biomarkers versus placebo. The drug showed a favorable safety profile and greater efficacy in high-inflammation subgroups, supporting advancement to Phase 3 trials.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in BioVie - Class A is now worth
$ 0.19
Resulting in a loss of
$ 99.81 (99.81%)
Note: Past profits do not guarantee future returns.
